{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T20:50:23Z","timestamp":1782420623794,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000805","name":"ECDC","doi-asserted-by":"crossref","award":["ECDC\/2021\/018"],"award-info":[{"award-number":["ECDC\/2021\/018"]}],"id":[{"id":"10.13039\/501100000805","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"DOI":"10.1186\/s12874-025-02742-8","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:16:07Z","timestamp":1765966567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Unmeasured confounding and misclassification in studies estimating vaccine effectiveness against hospitalisation and death using electronic health records (EHRs): an evaluation of a multi-country European retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"James","family":"Humphreys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toon","family":"Braeye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaak","family":"Van Evercooren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Holm","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Rask","family":"Moustsen-Helms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mateo-Urdiales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Castilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Mart\u00ednez-Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ausenda","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brechje","family":"de Gier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinta","family":"Meijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Bacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baltazar","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"VEBIS-EHR working group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"2742_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-publhealth-032315-021353","volume":"37","author":"JA Casey","year":"2016","unstructured":"Casey JA, Schwartz BS, Stewart WF, Adler NE. Using electronic health records for population health research: a review of methods and applications. Annu Rev Public Health. 2016;37:61\u201381.","journal-title":"Annu Rev Public Health"},{"issue":"10309","key":"2742_CR2","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. The Lancet. 2021;398(10309):1407\u201316.","journal-title":"The Lancet"},{"issue":"10316","key":"2742_CR3","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","volume":"398","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Cohen C, Hern\u00e1n MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093\u2013100.","journal-title":"Lancet"},{"issue":"12","key":"2742_CR4","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","volume":"27","author":"P Tang","year":"2021","unstructured":"Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27(12):2136\u201343.","journal-title":"Nat Med"},{"issue":"10285","key":"2742_CR5","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","volume":"397","author":"E Vasileiou","year":"2021","unstructured":"Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646\u201357.","journal-title":"Lancet"},{"key":"2742_CR6","doi-asserted-by":"publisher","unstructured":"Tessier E, Stowe J, Tsang C, Rai Y, Clarke E, Lakhani A, et al. Monitoring the COVID-19 immunisation programme through a National Immunisation Management System - England\u2019s experience. medRxiv; 2021:2021.09.14.21263578. Available from: https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2021.09.14.21263578v1. Cited 2025 Jan 7.","DOI":"10.1101\/2021.09.14.21263578v1"},{"issue":"38","key":"2742_CR7","doi-asserted-by":"publisher","first-page":"2100833","DOI":"10.2807\/1560-7917.ES.2021.26.38.2100833","volume":"26","author":"B Nunes","year":"2021","unstructured":"Nunes B, Rodrigues AP, Kislaya I, Cruz C, Peralta-Santos A, Lima J, et al. mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021. Eurosurveillance. 2021;26(38):2100833.","journal-title":"Eurosurveillance"},{"key":"2742_CR8","doi-asserted-by":"publisher","unstructured":"Moustsen-Helms IR, Emborg HD, Nielsen J, Nielsen KF, Krause TG, M\u00f8lbak K, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers - a Danish cohort study. medRxiv; 2021:2021.03.08.21252200. Available from: https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2021.03.08.21252200v1. Cited 2025 Jan 7.","DOI":"10.1101\/2021.03.08.21252200v1"},{"key":"2742_CR9","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.17.2100420","author":"M Fabiani","year":"2021","unstructured":"Fabiani M, Ramigni M, Gobbetto V, Mateo-Urdiales A, Pezzotti P, Piovesan C. Effectiveness of the Comirnaty (BNT162b2, BioNTech\/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. Euro Surveill. 2021. https:\/\/doi.org\/10.2807\/1560-7917.ES.2021.26.17.2100420.","journal-title":"Euro Surveill"},{"key":"2742_CR10","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m P, Ballin M, Nordstr\u00f6m A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Lancet Reg Health - Eur. 2021;11. Available from: https:\/\/www.thelancet.com\/journals\/lanepe\/article\/PIIS2666-77622100235-0\/fulltext. Cited 2025 Jan 7.","DOI":"10.1016\/j.lanepe.2021.100249"},{"issue":"21","key":"2742_CR11","doi-asserted-by":"publisher","first-page":"2100438","DOI":"10.2807\/1560-7917.ES.2021.26.21.2100438","volume":"26","author":"I Mart\u00ednez-Baz","year":"2021","unstructured":"Mart\u00ednez-Baz I, Miqueleiz A, Casado I, Navascu\u00e9s A, Trobajo-Sanmart\u00edn C, Burgui C, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Eurosurveillance. 2021;26(21):2100438.","journal-title":"Eurosurveillance"},{"issue":"31","key":"2742_CR12","doi-asserted-by":"crossref","first-page":"2100640","DOI":"10.2807\/1560-7917.ES.2021.26.31.2100640","volume":"26","author":"B de Gier","year":"2021","unstructured":"de Gier B, Andeweg S, Joosten R, ter Schegget R, Smorenburg N, van de Kassteele J, et al. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021. Eurosurveillance. 2021;26(31):2100640.","journal-title":"Eurosurveillance"},{"issue":"10","key":"2742_CR13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/pds.3856","volume":"24","author":"S Lanes","year":"2015","unstructured":"Lanes S, Brown JS, Haynes K, Pollack MF, Walker AM. Identifying health outcomes in healthcare databases. Pharmacoepidemiol Drug Saf. 2015;24(10):1009\u201316.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"2742_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40471-018-0164-x","volume":"5","author":"JC Young","year":"2018","unstructured":"Young JC, Conover MM, Funk MJ. Measurement error and misclassification in electronic medical records: methods to mitigate bias. Curr Epidemiol Rep. 2018;5(4):343\u201356.","journal-title":"Curr Epidemiol Rep"},{"issue":"6","key":"2742_CR15","doi-asserted-by":"publisher","first-page":"e0199180","DOI":"10.1371\/journal.pone.0199180","volume":"13","author":"TD Smedt","year":"2018","unstructured":"Smedt TD, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K. Bias due to differential and non-differential disease- and exposure misclassification in studies of vaccine effectiveness. PLoS ONE. 2018;13(6):e0199180.","journal-title":"PLoS ONE"},{"issue":"4","key":"2742_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1071\/PY14071","volume":"21","author":"R Bailie","year":"2015","unstructured":"Bailie R, Bailie J, Chakraborty A, Swift K. Consistency of denominator data in electronic health records in Australian primary healthcare services: enhancing data quality. Aust J Prim Health. 2015;21(4):450\u20139.","journal-title":"Aust J Prim Health"},{"issue":"5","key":"2742_CR17","doi-asserted-by":"publisher","first-page":"e0251622","DOI":"10.1371\/journal.pone.0251622","volume":"16","author":"U Baum","year":"2021","unstructured":"Baum U, Kulathinal S, Auranen K. Exposure misclassification bias in the estimation of vaccine effectiveness. PLoS ONE. 2021;16(5):e0251622.","journal-title":"PLoS ONE"},{"issue":"3","key":"2742_CR18","doi-asserted-by":"publisher","first-page":"dyae077","DOI":"10.1093\/ije\/dyae077","volume":"53","author":"C Sacco","year":"2024","unstructured":"Sacco C, Manica M, Marziano V, Fabiani M, Mateo-Urdiales A, Guzzetta G, et al. The impact of underreported infections on vaccine effectiveness estimates derived from retrospective cohort studies. Int J Epidemiol. 2024;53(3):dyae077.","journal-title":"Int J Epidemiol."},{"issue":"1","key":"2742_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/ije\/dyp332","volume":"39","author":"RHH Groenwold","year":"2010","unstructured":"Groenwold RHH, Nelson DB, Nichol KL, Hoes AW, Hak E. Sensitivity analyses to estimate the potential impact of unmeasured confounding in causal research. Int J Epidemiol. 2010;39(1):107\u201317.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2742_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s12879-015-1154-y","volume":"15","author":"C Remschmidt","year":"2015","unstructured":"Remschmidt C, Wichmann O, Harder T. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review. BMC Infect Dis. 2015;15(1):429.","journal-title":"BMC Infect Dis"},{"key":"2742_CR21","doi-asserted-by":"crossref","unstructured":"Doll MK, Pettigrew SM, Ma J, Verma A. Effects of Confounding Bias in COVID-19 and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors. medRxiv; 2021:2021.10.22.21265390. Available from:\u00a0https:\/\/www.medrxiv.org\/content\/10.1101\/2021.10.22.21265390v1. Cited 2024 Dec 12.","DOI":"10.1101\/2021.10.22.21265390"},{"issue":"5","key":"2742_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/irv.12999","volume":"16","author":"MM Loiacono","year":"2022","unstructured":"Loiacono MM, Van Aalst R, Pokutnaya D, Mahmud SM, Nealon J. Methods to account for measured and unmeasured confounders in influenza relative vaccine effectiveness studies: a brief review of the literature. Influenza Other Respir Viruses. 2022;16(5):846\u201350.","journal-title":"Influenza Other Respir Viruses"},{"issue":"21","key":"2742_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12874-021-01416-5","volume":"27","author":"MA Gianfrancesco","year":"2021","unstructured":"Gianfrancesco MA, Goldstein ND. A narrative review on the validity of electronic health record-based research in epidemiology. BMC Med Res Methodol. 2021;27(21):234.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"2742_CR24","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00125-017-4518-6","volume":"61","author":"R Farmer","year":"2018","unstructured":"Farmer R, Mathur R, Bhaskaran K, Eastwood SV, Chaturvedi N, Smeeth L. Promises and pitfalls of electronic health record analysis. Diabetologia. 2018;61(6):1241\u20138.","journal-title":"Diabetologia"},{"key":"2742_CR25","unstructured":"Protocol for a COVID-19 vaccine effectiveness estimation using health data registries, VEBIS multi-country study - Version 2.0. 2024. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/protocol-covid-19-vaccine-effectiveness-estimation-using-health-data-registries. Cited 2024 Dec 12."},{"issue":"4","key":"2742_CR26","doi-asserted-by":"publisher","first-page":"e13292","DOI":"10.1111\/irv.13292","volume":"18","author":"S Monge","year":"2024","unstructured":"Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al. Effectiveness of XBB.1.5 monovalent COVID-19 vaccines during a period of XBB.1.5 dominance in EU\/EEA countries, october to november 2023: a VEBIS-EHR network study. Influenza Other Respir Viruses. 2024;18(4):e13292.","journal-title":"Influenza Other Respir Viruses"},{"issue":"11","key":"2742_CR27","doi-asserted-by":"publisher","first-page":"e13195","DOI":"10.1111\/irv.13195","volume":"17","author":"I Kislaya","year":"2023","unstructured":"Kislaya I, Sent\u00eds A, Starrfelt J, Nunes B, Mart\u00ednez-Baz I, Nielsen KF, et al. Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in \u226565 years old population in six European countries, October 2021 to November 2022. Influenza Other Respir Viruses. 2023;17(11):e13195.","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"2742_CR28","doi-asserted-by":"publisher","first-page":"2300670","DOI":"10.2807\/1560-7917.ES.2024.29.1.2300670","volume":"29","author":"M Font\u00e1n-Vela","year":"2024","unstructured":"Font\u00e1n-Vela M, Kissling E, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al. Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged \u2265 65 years: results from a VEBIS network, Europe, October 2021 to July 2023. Euro Surveill. 2024;29(1):2300670.","journal-title":"Euro Surveill"},{"issue":"1","key":"2742_CR29","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14760584.2024.2428800","volume":"23","author":"B Nunes","year":"2024","unstructured":"Nunes B, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al. Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86\/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study. Expert Rev Vaccines. 2024;23(1):1085\u201390.","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"2742_CR30","doi-asserted-by":"publisher","first-page":"2400450","DOI":"10.2807\/1560-7917.ES.2025.30.8.2400450","volume":"30","author":"P Soares","year":"2025","unstructured":"Soares P, Machado A, Nicolay N, Monge S, Sacco C, Hansen CH, et al. COVID-19 vaccine effectiveness in the paediatric population aged 5\u201317 years: a multicentre cohort study using electronic health registries in six European countries, 2021 to 2022. Eurosurveillance. 2025;30(8):2400450.","journal-title":"Eurosurveillance"},{"key":"2742_CR31","unstructured":"Chapter 10: Analysing data and undertaking meta-analyses. Available from: https:\/\/training.cochrane.org\/handbook\/current\/chapter-10. Cited 2025 Mar 3."},{"key":"2742_CR32","unstructured":"European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials: Step 5. European Medicines Agency, Committee for Medicinal Products for Human Use. 2020."},{"issue":"3","key":"2742_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383.","journal-title":"Epidemiology"},{"key":"2742_CR34","doi-asserted-by":"publisher","unstructured":"Chow JY, Goh ZJ, Li R, Lim DZY, Wee LE, Lye DCB, Tan KB, Lim JT. Approaches for estimating COVID-19 vaccine effectiveness using observational data in administrative databases: a systematic review. medRxiv. 2025 Sep 30;2025.09.29.25336864. https:\/\/doi.org\/10.1101\/2025.09.29.25336864.","DOI":"10.1101\/2025.09.29.25336864"},{"issue":"12","key":"2742_CR35","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/jech.56.12.951","volume":"56","author":"E Hak","year":"2002","unstructured":"Hak E, Verheij TJM, Grobbee DE, Nichol KL, Hoes AW. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Community Health. 2002;56(12):951\u20135.","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"2742_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ije\/dyi274","volume":"35","author":"LA Jackson","year":"2006","unstructured":"Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006;35(2):337\u201344.","journal-title":"Int J Epidemiol"},{"issue":"10","key":"2742_CR37","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S1473-3099(07)70236-0","volume":"7","author":"L Simonsen","year":"2007","unstructured":"Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007;7(10):658\u201366.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"2742_CR38","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/aje\/kwt124","volume":"178","author":"ML Jackson","year":"2013","unstructured":"Jackson ML, Yu O, Nelson JC, Naleway A, Belongia EA, Baxter R, et al. Further Evidence for Bias in Observational Studies of Influenza Vaccine Effectiveness: The 2009 Influenza A(H1N1) Pandemic. Am J Epidemiol. 2013;178(8):1327\u201336.","journal-title":"Am J Epidemiol"},{"issue":"30","key":"2742_CR39","doi-asserted-by":"publisher","first-page":"e1240","DOI":"10.1097\/MD.0000000000001240","volume":"94","author":"J Castilla","year":"2015","unstructured":"Castilla J, Guevara M, Mart\u00ednez-Baz I, Ezpeleta C, Delfrade J, Irisarri F, et al. Enhanced estimates of the influenza vaccination effect in preventing mortality: a prospective cohort study. Medicine (Baltimore). 2015;94(30):e1240.","journal-title":"Medicine (Baltimore)"},{"key":"2742_CR40","unstructured":"Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, et al. Assessing Healthy Vaccinee Effect in COVID-19 Vaccine Effectiveness Studies: A National Cohort Study in Qatar. medRxiv; 2024:2024.07.28.24311115. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2024.07.28.24311115v2. Cited 2025 Jan 8."},{"issue":"2","key":"2742_CR41","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S1473-3099(23)00746-6","volume":"24","author":"CH Hansen","year":"2024","unstructured":"Hansen CH, Moustsen-Helms IR, Rasmussen M, S\u00f8borg B, Ullum H, Valentiner-Branth P. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study. Lancet Infect Dis. 2024;24(2):e73\u20134.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2742_CR42","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/S1473-3099(24)00106-3","volume":"24","author":"E Poukka","year":"2024","unstructured":"Poukka E, Auranen K, Baum U. Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies. Lancet Infect Dis. 2024;24(5):e275.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2742_CR43","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1016\/S1473-3099(24)00107-5","volume":"24","author":"CH Hansen","year":"2024","unstructured":"Hansen CH, Moustsen-Helms IR, Rasmussen M, S\u00f8borg B, Ullum H, Valentiner-Branth P. Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies - Authors\u2019 reply. Lancet Infect Dis. 2024;24(5):e276.","journal-title":"Lancet Infect Dis"},{"key":"2742_CR44","unstructured":"European Health Data Space - European Commission. 2024. Available from: https:\/\/health.ec.europa.eu\/ehealth-digital-health-and-care\/european-health-data-space_en. Cited 2024 Oct 31."},{"key":"2742_CR45","unstructured":"Framework for financial data access - European Commission. Available from: https:\/\/finance.ec.europa.eu\/digital-finance\/framework-financial-data-access_en. Cited 2025 Mar 5."},{"key":"2742_CR46","doi-asserted-by":"publisher","first-page":"100996","DOI":"10.1016\/j.lanepe.2024.100996","volume":"44","author":"M Pizzato","year":"2024","unstructured":"Pizzato M, Gerli AG, La Vecchia C, Alicandro G. Impact of COVID-19 on total excess mortality and geographic disparities in Europe, 2020\u20132023: a spatio-temporal analysis. Lancet Reg Health. 2024;44:100996. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100996.","journal-title":"Lancet Reg Health"},{"key":"2742_CR47","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/pds.4801","volume":"28","author":"HS Izurieta","year":"2019","unstructured":"Izurieta HS, Wu X, Lu Y, Chillarige Y, Wenecke M, Lindaas A, et al. Zostavax vaccine effectiveness among US elderly using real-world evidence: addressing unmeasured confounders by multiple imputation after linking beneficiary surveys with medicare claims. Pharmacoepidemiol Drug Saf. 2019;28:993\u20131001. https:\/\/doi.org\/10.1002\/pds.4801.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2742_CR48","doi-asserted-by":"publisher","first-page":"e4251","DOI":"10.1093\/cid\/ciaa1727","volume":"73","author":"HS Izurieta","year":"2021","unstructured":"Izurieta HS, Lu M, Kelman J, Lu Y, Lindaas A, Loc J, et al. Comparative effectiveness of influenza vaccines among US medicare beneficiaries ages 65 years and older during the 2019\u20132020 season. Clin Infect Dis. 2021;73:e4251\u20139. https:\/\/doi.org\/10.1093\/cid\/ciaa1727.","journal-title":"Clin Infect Dis"},{"key":"2742_CR49","unstructured":"Double Negative Control Inference in Test-Negative Design Studies of Vaccine Effectiveness - PMC. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8963685\/. Cited 2025 Apr 30."},{"issue":"3","key":"2742_CR50","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/01.ede.0000215160.88317.cb","volume":"17","author":"EP Martens","year":"2006","unstructured":"Martens EP, Pestman WR, de Boer A, Belitser SV, Klungel OH. Instrumental variables: application and limitations. Epidemiol Camb Mass. 2006;17(3):260\u20137.","journal-title":"Epidemiol Camb Mass"},{"issue":"6","key":"2742_CR51","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/pds.1908","volume":"19","author":"MA Brookhart","year":"2010","unstructured":"Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf. 2010;19(6):537\u201354.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"2742_CR52","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/j.1541-0420.2005.00377.x","volume":"61","author":"H Bang","year":"2005","unstructured":"Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. Biometrics. 2005;61(4):962\u201373.","journal-title":"Biometrics"},{"issue":"7","key":"2742_CR53","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kwq439","volume":"173","author":"MJ Funk","year":"2011","unstructured":"Funk MJ, Westreich D, Wiesen C, St\u00fcrmer T, Brookhart MA, Davidian M. Doubly Robust Estimation of Causal Effects. Am J Epidemiol. 2011;173(7):761\u20137.","journal-title":"Am J Epidemiol"},{"key":"2742_CR54","unstructured":"Self-controlled case series methods: an alternative to standard epidemiological study designs. The BMJ. Available from: https:\/\/www.bmj.com\/content\/354\/bmj.i4515. Cited 2025 Mar 5."}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-025-02742-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-025-02742-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-025-02742-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:48:55Z","timestamp":1768992535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12874-025-02742-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2742"],"URL":"https:\/\/doi.org\/10.1186\/s12874-025-02742-8","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study sites participating in this study conformed with their respective national and EU ethical and data protection requirements. Ethical statements for each of the participating study sites:Belgium: Data linkage and collection within the data-warehouse have been approved by the information security committee. The study was conducted in accordance with the Declaration of Helsinki. Ethical approval was granted for the gathering of data from hospitalised patients by the Committee for Medical Ethics from the Ghent University Hospital (reference number BC-07507) and authorisation for possible individual data linkage using the national register number from the Information Security Committee (ISC) Social Security and Health (reference number IVC\/KSZG\/20\/384). Linkage of hospitalised patient data to vaccination and testing within the LINK-VACC project was approved by the Medical Ethics Committee UZ Brussels-VUB on 3 February 2021 (reference number 2020\/523), and authorisation from the ISC Social Security and Health (reference number IVC\/KSZG\/21\/034).Denmark: Only administrative register data was used for the study. According to Danish law, ethics approval is exempt for such research, and the Danish Data Protection Agency, which is dedicated ethics and legal oversight body, thus waives ethical approval for the study of administrative register data when no individual contact of participants is necessary, and only aggregate results are included as findings. The study is, therefore, fully compliant with all legal and ethical requirements, and there are no further processes available regarding such studies.Navarre (Spain): The study was approved by Navarre\u2019s Ethical Committee for Clinical Research, which waived the requirement of obtaining informed consent.Norway: Ethical approval was granted by Regional Committees for Medical and Health Research Ethics (REC) Southeast (reference number 122745). The Norwegian Institute of Public Health has performed a Data Protection Impact Assessment (DPIA) for Beredt C19.Portugal: The study received approval from the Ethical Committee and the Data Protection Officer of the Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge. Given that data was irreversibly anonymised, the need for the participants\u2019 informed consent was waived by the Ethical Committee.Italy: This study, based on routinely collected data, was not submitted for approval to an ethical committee because the dissemination of COVID-19 surveillance data was authorised by the Italian law N. 52 of 19 May 2022, following the law decree N. 24 of 24 March 2022 (Article n. 13). Based on the same acts, the information on COVID-19 vaccination was retrieved by the Italian National Institute of Health using data from the National Immunisation Information System of the Italian Ministry of Health. Because of the retrospective design and the large size of the population under study, in accordance with the Authorisation n. 9 released by the Italian data protection authority on 15 December 2016, the individual informed consent was not requested for the conduction of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}